ProKidney vs SAB Biotherapeutics
PROK and SABS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PROK and SABS compare
ProKidney is the larger company, worth 1.2 times as much as SAB Biotherapeutics ($342M against $283M).
SAB Biotherapeutics scores higher on the StockData Score (8 against 5 for ProKidney), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PROK | SABS |
|---|---|---|
| Size and price | ||
| Market cap | $342M | $283M |
| Share price | $1.13 | $3.11 |
| Change, 1 year | −58.1% | −2.8% |
| Change, 5 years | −88.6% | −97.2% |
| Beta (5Y) | 1.32 | 1.39 |
| Employees | 231 | 86 |
| StockData Score | ||
| Total score | 5 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 418× | – |
| P/B | – | 1.3× |
| FCF yield | −46.8% | – |
| Growth | ||
| Revenue growth (TTM) | 55.2% | – |
| Net income growth (TTM) | – | −530% |
| Profitability | ||
| Operating margin | −21665% | – |
| Net margin | −10288% | – |
| FCF margin | −19527% | – |
| Return on equity | – | −42.8% |
| Return on invested capital | – | −83.4% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −9327.2× | – |
| Current ratio | 8.36 (better) | 7.28 |
| Altman Z-score | −1.12 | 5.11 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −7.1% | – |
| Shareholder yield | −7.1% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 16.1% | 75.2% |
| Held by insiders | 62.9% | 30.2% |
| Insider net buying, 12 months | −$1.1M | – |
| Short interest, % of float | 21.7% | 7.9% |
Go deeper
- PROK stock overview
- PROK income statement
- PROK valuation and score
- SABS stock overview
- SABS income statement
- SABS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.